Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tohoku Univ., Drug Makers, MICIN to Jointly Collect Lifestyle Data with Wearable
Tohoku University’s Tohoku Medical Megabank Organization (ToMMo), Daiichi Sankyo, Takeda Pharmaceutical, and MICIN said on May 23 that they have launched a collaborative research project aimed at gathering a year’s worth of lifestyle data through a wearable device. Under the…
To read the full story
Related Article
- Tohoku Univ, JPMA, MICIN Launch Pilot Study on Wearable Data Collection
December 24, 2020
- Takeda, Tohoku University Ink Joint Research Pact on Whole Genome Sequencing
April 20, 2020
- Tohoku Medical Megabank, JPMA Initiate Joint Research on Preventive and Preemptive Health
April 2, 2020
- JPMA, Tohoku Medical Megabank to Start Collaborative Research on Preemptive Health
January 30, 2020
- Pharma Companies Mull Use of Tohoku University’s Database for Drug Discovery: JPMA Official
December 18, 2018
BUSINESS
- Japan Pharma Workforce Up Slightly; Generic Firms Drive Gains over 5 Years
April 10, 2026
- Zenyaku, Chugai to End Rituxan Co-Promotion in September
April 10, 2026
- Effexor’s GAD Nod Seen Boosting Diagnosis, Treatment in Japan: Expert
April 10, 2026
- MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
- Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…